On the contrary, miR-1 showed an increasing trend over time in all subjects, in comparison to baseline levels, and a significant upregulation in cardiotoxicity-affected vs. non-cardiotoxic patients after cycle 2, 3, and 4.
← all excerpts
Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
1
—
—